Nebenwirkungen · Nimenrix
Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine · Abschnitt 4.8 · PDF-Seite 6
HOS-213764 · Präparat HOS-155198
The safety of Nimenrix presented in the table below is based on two clinical study datasets as follows: A pooled analysis of data from 9,621 subjects administered a single dose of Nimenrix. This total included 3,079 toddlers (12 months to 23 months), 909 children between 2 and 5 years of age, 990 children between 6 and 10 years of age, 2,317 adolescents (11 to 17 years) and 2,326 adults (18 to 55 years). Data from a study in infants aged 6 to 12 weeks at the time of the first dose (Study MenACWY-TT-083), 1,052 subjects received at least one dose of a primary series of 2 or 3 doses of Nimenrix and 1,008 received a booster dose at approximately 12 months of age.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-13T13:10:00Z · SHA-256 47ca5a942f5fe1d6ee76efb76a4a7dbc6147fbdb447af3923eb0bf5adf5d0d4d · Passage 15104b13b819797dbe86d313e1d2611186e88bc5953f895d3aab2a68ae3f06a9 · Zeichen 31–737 im Abschnitt